1 / 13

Safety and Efficacy of Anti-Cholesterol Medication in Soft Drusen Patients

Safety and Efficacy of Anti-Cholesterol Medication in Soft Drusen Patients. Kontari , Ioanna MD 1 Georgalas , Ilias , MD 1 Kanellopoulos, Anastasios - John MD 1,2 1 : Laservision.gr Institute, Athens, Greece 2 : NYU Medical School, New York, NY

faith
Télécharger la présentation

Safety and Efficacy of Anti-Cholesterol Medication in Soft Drusen Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Safety and Efficacy of Anti-Cholesterol Medication in Soft DrusenPatients Kontari, IoannaMD 1 Georgalas, Ilias, MD 1 Kanellopoulos, Anastasios-John MD 1,2 1: Laservision.gr Institute, Athens, Greece 2: NYU Medical School, New York, NY Financial Interests: Kontari: none; Georgalas: none, Kanellopoulos: Alcon/WaveLight, Avedro

  2. To investigate hypolipidaemic (cholesterol-lowering) statin effect in patients with ‘soft’ macular degeneration (Drusen). Purpose Setting • a modern ophthalmological surgical center.

  3. Background • Atorvastatin calcium (AC) is a cholesterol-lowering medication that lowers high levels of cholesterol and triglycerides in the blood, which helps reduce risk of heart disease. • The study will investigate the effects of AC on macular degeneration and on visual acuity improvement.

  4. AMD Pathology • Understanding of AMD pathology is rather incomplete • Matrix of risk factors • hereditary/ • non hereditary/environmental • Age • Smoking • Diet • Hypertension • Serum-Cholesterol levels • Cardiovascular disease

  5. AMD Pathology • Lipoproteins – synthesis at liver • Plasma: source of lipoproteins, accumulating in Bruch’s membrane • Drusen: contain* • material derived from RPE, choroid, plasma, • apolipoproteins, cholesterol, et cetera • * EbrahimiKB, Handa JT. • Lipids, lipoproteins, and age-related macular degeneration. J Lipids. 2011;2011:802059.

  6. Methods • This is a single center, comparison, single intervention case series, • 8 consecutive cases • 12 months follow up

  7. Eligibility Criteria • Age ≥ 50, • Clinical findings of hypercholesterolaemia (≥ 220 mg/dl), • Best-corrected distance visual acuity between 0.3 and 0.7, • Soft Drusenmacular findings (dry AMD), • No eye previously been treated with anti-vascular endothelial growth factor medications, • Phackic eyes.

  8. Methods • Posterior Segment Exam protocol: • Optical coherence tomography documentation of existing (pre-medicative) condition of dry AMD (soft Drusen macular findings ), • three months and six months post-medicative follow-up per patient.

  9. Medication • 40 mgr /day per os • 6-month administration • In cooperation with attending physician • Mean age 67 ± 13 (55 to 72) years, • 5 female, 3 male patients,

  10. Results • Pre-medication data • Cholesterol 265 ± 45 (225 to 290) mg/dl • Mean IOP 16.2 ± 2.1 (14 to 21) mmHg, • Mean CDVA 0.55 ± 2 (0.4 to 0.7), • Post-medication data • Cholesterol 235 ± 17 (205 to 250) mg/dl (p < 0.05), • Mean IOP 16.3 ± 2.2 (14 to 21) mmHg (p = 0.195), • Mean CDVA 0.62 ± 2 (0.5 to 0.8) (p = 0.05).

  11. Results Post-medication Pre-medication

  12. Conclusions • Administration of anti-cholesterol medication appears to have collateral benefit in stabilization and/or reduction of existing soft-Drusen AMD • More vigorous studies, extended follow-up, and larger sample investigation is recommended.

  13. Thank you www.laservision.gr

More Related